Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives $10M from Takeda for Tech Transfer

Premium

Alnylam Pharmaceuticals said this week that it has received a $10 million payment from partner Takeda Pharmaceutical related to an alliance the companies formed in 2008.

According to Alnylam, the payment is specifically tied to the achievement of undisclosed objectives in the transfer of its platform technology, including documents, materials, and know-how to the Japanese firm for the development of RNAi-based therapeutics.

In mid-2008, Alnylam announced that it had signed a deal giving Takeda worldwide, non-exclusive access to its RNAi intellectual property and technology to help develop drugs for cancer and metabolic diseases (GSN 5/29/2008). In exchange, Alnylam received $150 million upfront, and was eligible to receive $50 million in technology-transfer payments, and up to $171 million in development and commercial milestones, as well as royalties.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.